Ticagrelor

CAS: 274693-27-5

Ref. TM-T0179

Produktinformation

• Name: Ticagrelor
• Synonyme: AR-C 126532XX, AZD6140, (1S,2S,3R,5S)-3-(7-(((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol, (1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-Difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-1,2-cyclopentanediol, 1,2-Cyclopentanediol, 3-[7-[[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-, (1S,2S,3R,5S)-, Ar-C 126532Xx, Ar-C126532, Azd 6140, Azd6140, Brilinta, Brilique, Possia, Triafluocyl
• CAS: 274693-27-5

Beschreibung

Ticagrelor (AR-C 126532XX), produced by AstraZeneca, is an inhibitor of platelet aggregation. Unlike clopidogrel, ticagrelor is not a prodrug required metabolic activation. The drug was approved for use in the European Union by the European Commission on December 3, 2010, and by the US FDA on July 20, 2011. Its trade names are Brilinta (US), Brilique(EU) and Possia(EU).

• Marke: Targetmol

Chemische Eigenschaften

• Molekulargewicht: 522.57
• Formel: C₂₃H₂₈F₂N₆O₄S
• Reinheit: 100%
• Farbe/Form: Solid